The Scottish Medicines Consortium (SMC) have approved ‘Fampyra’ for use by people living with multiple sclerosis (MS) in Scotland. Around 2 in 3 people with MS will develop walking difficulties and the drug, fampridine, improves walking ability in those responsive to it; around 1 in 3 people who try it (Biogen).

Developed by Biogen Idec, fampridine can cause substantial improvements in routine day-to-day functional activities for patients responding to the treatment. This has included the ability to walk independently and unaided for sufficient enough time to manage daily tasks (Hupperts: 2016; Goodman: 2015; Hobart: 2019).

In January, the drug was licensed for use in Wales, and now those with MS living in Scotland will be able to access the treatment too. 

For further information, the MS Trust have a helpful amount of information about fampridine on their website.

Fampyra-SMC-approval-release

  

Posted in:

Subscribe
Notify of
guest
1 Comment
oldest
newest most voted
Inline feedbacks
View all comments
Ronald

Topline results from the study have been announced in a press release from the manufacturer, MedDay. Detailed results of the study will be presented at the American Academy of Neurology (AAN) meeting in Toronto, April 2020.